Tempest Historical Financial Ratios

TPST Stock  USD 1.10  0.01  0.92%   
Tempest Therapeutics is promptly reporting on over 85 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 1.65, Invested Capital of 0.0, Average Payables of 0.0 or Stock Based Compensation To Revenue of 21.71 will help investors to properly organize and evaluate Tempest Therapeutics financial condition quickly.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

About Tempest Financial Ratios Analysis

Tempest TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Tempest Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Tempest financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Tempest Therapeutics history.

Tempest Therapeutics Financial Ratios Chart

At this time, Tempest Therapeutics' PTB Ratio is comparatively stable compared to the past year. Stock Based Compensation To Revenue is likely to gain to 21.71 in 2024, whereas Free Cash Flow Yield is likely to drop (0.43) in 2024.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On EquityOperating Cycle
Cash Conversion Cycle

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Tempest Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Tempest Therapeutics sales, a figure that is much harder to manipulate than other Tempest Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Tempest Therapeutics dividend as a percentage of Tempest Therapeutics stock price. Tempest Therapeutics dividend yield is a measure of Tempest Therapeutics stock productivity, which can be interpreted as interest rate earned on an Tempest Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.
Most ratios from Tempest Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Tempest Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.At this time, Tempest Therapeutics' PTB Ratio is comparatively stable compared to the past year. Stock Based Compensation To Revenue is likely to gain to 21.71 in 2024, whereas Free Cash Flow Yield is likely to drop (0.43) in 2024.
 2021 2023 2024 (projected)
Payables Turnover1.280.450.43
Days Of Inventory On Hand454.38408.94429.39

Tempest Therapeutics fundamentals Correlations

0.050.16-0.030.170.10.250.050.990.10.110.240.11-0.4-0.020.160.97-0.1-0.12-0.36-0.65-0.11-0.17-0.140.12-0.13
0.050.03-0.130.280.190.561.00.160.190.130.250.19-0.41-0.140.03-0.09-0.19-0.98-0.36-0.61-0.98-0.27-0.210.19-0.89
0.160.030.12-0.13-0.120.280.030.21-0.12-0.040.19-0.1-0.460.221.00.130.11-0.16-0.39-0.31-0.160.130.09-0.08-0.05
-0.03-0.130.12-0.86-0.97-0.14-0.13-0.04-0.97-0.980.17-0.98-0.34-0.330.12-0.010.980.13-0.370.150.130.58-0.83-0.980.07
0.170.28-0.13-0.860.950.320.280.20.950.88-0.160.950.150.32-0.130.13-0.95-0.280.14-0.37-0.29-0.520.630.93-0.17
0.10.19-0.12-0.970.950.220.190.131.00.98-0.171.00.260.34-0.120.07-1.0-0.190.26-0.26-0.2-0.560.771.0-0.11
0.250.560.28-0.140.320.220.560.380.220.230.390.22-0.66-0.10.280.07-0.22-0.67-0.63-0.84-0.69-0.260.010.24-0.19
0.051.00.03-0.130.280.190.560.160.190.130.250.19-0.41-0.140.03-0.09-0.19-0.98-0.36-0.61-0.98-0.27-0.210.19-0.89
0.990.160.21-0.040.20.130.380.160.130.140.290.14-0.5-0.040.210.93-0.13-0.24-0.44-0.74-0.24-0.21-0.160.15-0.19
0.10.19-0.12-0.970.951.00.220.190.130.98-0.171.00.260.34-0.120.07-1.0-0.190.27-0.26-0.2-0.560.771.0-0.11
0.110.13-0.04-0.980.880.980.230.130.140.98-0.090.980.230.3-0.040.08-0.98-0.150.23-0.25-0.16-0.510.810.99-0.05
0.240.250.190.17-0.16-0.170.390.250.29-0.17-0.09-0.15-0.73-0.320.190.180.16-0.32-0.56-0.4-0.330.21-0.33-0.11-0.16
0.110.19-0.1-0.980.951.00.220.190.141.00.98-0.150.250.34-0.10.09-1.0-0.190.26-0.26-0.2-0.550.771.0-0.11
-0.4-0.41-0.46-0.340.150.26-0.66-0.41-0.50.260.23-0.730.250.03-0.46-0.31-0.260.530.830.740.540.00.490.220.29
-0.02-0.140.22-0.330.320.34-0.1-0.14-0.040.340.3-0.320.340.030.220.1-0.340.130.25-0.090.14-0.520.280.330.05
0.160.031.00.12-0.13-0.120.280.030.21-0.12-0.040.19-0.1-0.460.220.130.11-0.16-0.39-0.31-0.160.130.09-0.08-0.05
0.97-0.090.13-0.010.130.070.07-0.090.930.070.080.180.09-0.310.10.13-0.080.05-0.25-0.520.05-0.13-0.130.1-0.04
-0.1-0.190.110.98-0.95-1.0-0.22-0.19-0.13-1.0-0.980.16-1.0-0.26-0.340.11-0.080.19-0.270.260.20.56-0.77-1.00.11
-0.12-0.98-0.160.13-0.28-0.19-0.67-0.98-0.24-0.19-0.15-0.32-0.190.530.13-0.160.050.190.480.711.00.270.19-0.20.84
-0.36-0.36-0.39-0.370.140.26-0.63-0.36-0.440.270.23-0.560.260.830.25-0.39-0.25-0.270.480.620.48-0.360.50.230.23
-0.65-0.61-0.310.15-0.37-0.26-0.84-0.61-0.74-0.26-0.25-0.4-0.260.74-0.09-0.31-0.520.260.710.620.710.380.11-0.280.43
-0.11-0.98-0.160.13-0.29-0.2-0.69-0.98-0.24-0.2-0.16-0.33-0.20.540.14-0.160.050.21.00.480.710.270.19-0.210.83
-0.17-0.270.130.58-0.52-0.56-0.26-0.27-0.21-0.56-0.510.21-0.550.0-0.520.13-0.130.560.27-0.360.380.27-0.35-0.550.21
-0.14-0.210.09-0.830.630.770.01-0.21-0.160.770.81-0.330.770.490.280.09-0.13-0.770.190.50.110.19-0.350.770.3
0.120.19-0.08-0.980.931.00.240.190.151.00.99-0.111.00.220.33-0.080.1-1.0-0.20.23-0.28-0.21-0.550.77-0.11
-0.13-0.89-0.050.07-0.17-0.11-0.19-0.89-0.19-0.11-0.05-0.16-0.110.290.05-0.05-0.040.110.840.230.430.830.210.3-0.11
Click cells to compare fundamentals

Tempest Therapeutics Account Relationship Matchups

Tempest Therapeutics fundamentals Accounts

201920202021202220232024 (projected)
Ptb Ratio1.58(0.0146)0.550.732.533.14
Book Value Per Share65.52(2.2K)9.531.571.741.65
Free Cash Flow Yield(0.45)(19.03)(1.3)(2.38)(0.41)(0.43)
Operating Cash Flow Per Share(45.11)(609.32)(6.85)(2.69)(1.77)(1.86)
Capex To Depreciation0.380.150.360.880.450.42
Pb Ratio1.58(0.0146)0.550.732.533.14
Free Cash Flow Per Share(45.55)(610.93)(6.88)(2.74)(1.79)(1.87)
Roic(0.75)0.29(0.52)(0.89)(0.76)(0.8)
Net Income Per Share(48.77)(612.56)(7.8)(3.18)(1.91)(2.01)
Payables Turnover0.70.761.281.640.450.43
Cash Per Share69.5603.0113.672.72.542.42
Pocfratio(2.24)(0.0527)(0.77)(0.43)(2.48)(2.6)
Capex To Operating Cash Flow(0.009631)(0.002629)(0.005201)(0.0181)(0.006214)(0.006525)
Pfcf Ratio(2.22)(0.0525)(0.77)(0.42)(2.46)(2.59)
Days Payables Outstanding518.7479.65284.81222.94809.51769.04
Pe Ratio(2.07)(0.0524)(0.68)(0.36)(2.3)(2.42)
Return On Tangible Assets(0.59)(0.84)(0.4)(0.8)(0.57)(0.6)
Earnings Yield(0.48)(19.08)(1.48)(2.77)(0.43)(0.46)
Net Debt To E B I T D A1.330.861.250.270.650.76
Current Ratio5.686.153.444.534.297.98
Tangible Book Value Per Share65.52(2.2K)9.531.571.741.65
Graham Number265.165.5K40.8810.68.658.21
Shareholders Equity Per Share64.07(2.2K)9.531.571.741.65
Debt To Equity0.0363(0.0355)0.511.220.430.29
Capex Per Share0.431.60.03560.04870.0110.0105
Graham Net Net54.03(2.3K)7.060.310.930.89
Interest Debt Per Share1.1978.155.232.050.840.8

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.